Renal Cell Carcinoma: The Translation of Biology to Clinical Application

References 

1. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2006;24(18S):2s;(abstr LBA3)
2. Hudes G, Carducci M, Tomczak P, et al. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-prognosis patients with advanced renal cell carcinoma. J Clin Oncol. 2006;24(18S):2s;(abstr LBA4)